LU87982A1 - Procede de preparation de compositions a liberation prolongee et compositions ainsi obtenues - Google Patents

Procede de preparation de compositions a liberation prolongee et compositions ainsi obtenues Download PDF

Info

Publication number: LU87982A1
Authority: LU; Luxembourg
Prior art keywords: gel; particles; mpa; viscosity; phase
Prior art date: 1990-08-01

Application number

LU87982A

Other languages

English (en)

French (fr)

Inventor

Jean-Marc Ruiz

Original Assignee

Scras

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-08-01

Filing date

1991-07-25

Publication date

1992-04-15

1991-07-25 Application filed by Scras filed Critical Scras

1992-04-15 Publication of LU87982A1 publication Critical patent/LU87982A1/fr

Links

239000000203 mixture Substances 0.000 title claims description 18
238000000034 method Methods 0.000 title claims description 16
238000002360 preparation method Methods 0.000 title claims description 6
230000008569 process Effects 0.000 title description 5
238000013268 sustained release Methods 0.000 title description 5
239000012730 sustained-release form Substances 0.000 title description 5
239000002245 particle Substances 0.000 claims description 31
239000011325 microbead Substances 0.000 claims description 18
229920001577 copolymer Polymers 0.000 claims description 10
230000002209 hydrophobic effect Effects 0.000 claims description 8
239000000470 constituent Substances 0.000 claims description 6
238000000227 grinding Methods 0.000 claims description 6
238000003756 stirring Methods 0.000 claims description 4
229920002988 biodegradable polymer Polymers 0.000 claims description 3
239000004621 biodegradable polymer Substances 0.000 claims description 3
230000015572 biosynthetic process Effects 0.000 claims description 3
238000001914 filtration Methods 0.000 claims description 3
238000001816 cooling Methods 0.000 claims description 2
238000001125 extrusion Methods 0.000 claims description 2
238000010438 heat treatment Methods 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
230000006835 compression Effects 0.000 claims 1
238000007906 compression Methods 0.000 claims 1
238000001035 drying Methods 0.000 claims 1
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 30
239000004480 active ingredient Substances 0.000 description 22
229920000642 polymer Polymers 0.000 description 20
239000000499 gel Substances 0.000 description 19
239000002904 solvent Substances 0.000 description 10
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 9
102100024028 Progonadoliberin-1 Human genes 0.000 description 9
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 9
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
239000003094 microcapsule Substances 0.000 description 7
239000005556 hormone Substances 0.000 description 6
PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
229940088597 hormone Drugs 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
108010021336 lanreotide Proteins 0.000 description 4
238000002844 melting Methods 0.000 description 4
230000008018 melting Effects 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
-1 PvP Substances 0.000 description 3
239000001768 carboxy methyl cellulose Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
235000014655 lactic acid Nutrition 0.000 description 3
239000004005 microsphere Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 3
150000003431 steroids Chemical class 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000005406 washing Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
108010050144 Triptorelin Pamoate Proteins 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000009826 distribution Methods 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000006870 function Effects 0.000 description 2
230000004927 fusion Effects 0.000 description 2
230000009477 glass transition Effects 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
229920001432 poly(L-lactide) Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000005563 spheronization Methods 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 2
229960004824 triptorelin Drugs 0.000 description 2
HUEYSSLYFJVUIS-MRFSYGAJSA-N (2s,3r,11bs)-2-[[(1r)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl]-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizine;hydron;chloride Chemical compound Cl.N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC HUEYSSLYFJVUIS-MRFSYGAJSA-N 0.000 description 1
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
108010001478 Bacitracin Proteins 0.000 description 1
102400000739 Corticotropin Human genes 0.000 description 1
101800000414 Corticotropin Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
108010021717 Nafarelin Proteins 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
108010093965 Polymyxin B Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
229930003779 Vitamin B12 Natural products 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
239000003263 anabolic agent Substances 0.000 description 1
229940124325 anabolic agent Drugs 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
239000004004 anti-anginal agent Substances 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
229940124345 antianginal agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
229940121357 antivirals Drugs 0.000 description 1
239000002830 appetite depressant Substances 0.000 description 1
238000000889 atomisation Methods 0.000 description 1
229960003071 bacitracin Drugs 0.000 description 1
229930184125 bacitracin Natural products 0.000 description 1
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
238000006065 biodegradation reaction Methods 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
229960001076 chlorpromazine Drugs 0.000 description 1
238000005354 coacervation Methods 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
229960000258 corticotropin Drugs 0.000 description 1
239000013078 crystal Substances 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000000113 differential scanning calorimetry Methods 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000007580 dry-mixing Methods 0.000 description 1
229960001923 emetine hydrochloride Drugs 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000007368 endocrine function Effects 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
230000035558 fertility Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000000380 hallucinogen Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
239000003688 hormone derivative Substances 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 1
229960002102 imipramine hydrochloride Drugs 0.000 description 1
238000007654 immersion Methods 0.000 description 1
230000001788 irregular Effects 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000012528 membrane Substances 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
229960004309 nafarelin acetate Drugs 0.000 description 1
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
229960004127 naloxone Drugs 0.000 description 1
239000004081 narcotic agent Substances 0.000 description 1
239000003887 narcotic antagonist Substances 0.000 description 1
NCYVXEGFNDZQCU-UHFFFAOYSA-N nikethamide Chemical compound CCN(CC)C(=O)C1=CC=CN=C1 NCYVXEGFNDZQCU-UHFFFAOYSA-N 0.000 description 1
229960003226 nikethamide Drugs 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
229940124641 pain reliever Drugs 0.000 description 1
229960001789 papaverine Drugs 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
229960000482 pethidine Drugs 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
229960002695 phenobarbital Drugs 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
229920002627 poly(phosphazenes) Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229960003548 polymyxin b sulfate Drugs 0.000 description 1
229920006324 polyoxymethylene Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229950008882 polysorbate Drugs 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000004810 polytetrafluoroethylene Substances 0.000 description 1
229920001343 polytetrafluoroethylene Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
229960003147 reserpine Drugs 0.000 description 1
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
238000004626 scanning electron microscopy Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
238000007873 sieving Methods 0.000 description 1
229920002545 silicone oil Polymers 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000000935 solvent evaporation Methods 0.000 description 1
239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
239000011715 vitamin B12 Substances 0.000 description 1
235000019163 vitamin B12 Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Biological Depolymerization Polymers (AREA)
Glanulating (AREA)
Manufacturing Of Micro-Capsules (AREA)
Cosmetics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LU87982A 1990-08-01 1991-07-25 Procede de preparation de compositions a liberation prolongee et compositions ainsi obtenues LU87982A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB909016885A GB9016885D0 (en)	1990-08-01	1990-08-01	Sustained release pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
LU87982A1 true LU87982A1 (fr)	1992-04-15

Family

ID=10679993

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU87982A LU87982A1 (fr)	1990-08-01	1991-07-25	Procede de preparation de compositions a liberation prolongee et compositions ainsi obtenues

Country Status (30)

Country	Link
US (1)	US5213812A (pt)
JP (1)	JP2818704B2 (pt)
KR (1)	KR920003962A (pt)
AT (1)	AT396425B (pt)
AU (2)	AU649696B2 (pt)
BE (1)	BE1004772A3 (pt)
CA (1)	CA2048270C (pt)
CH (1)	CH682715A5 (pt)
DE (1)	DE4125542A1 (pt)
DK (1)	DK175756B1 (pt)
ES (1)	ES2046083B1 (pt)
FI (1)	FI104149B (pt)
FR (1)	FR2665360B1 (pt)
GB (1)	GB9016885D0 (pt)
GR (1)	GR1001512B (pt)
HK (1)	HK33294A (pt)
IE (1)	IE65124B1 (pt)
IN (1)	IN178446B (pt)
IT (1)	IT1251788B (pt)
LU (1)	LU87982A1 (pt)
MA (1)	MA22245A1 (pt)
MY (1)	MY107500A (pt)
NL (1)	NL194637C (pt)
NO (1)	NO300158B1 (pt)
NZ (1)	NZ238981A (pt)
OA (1)	OA09387A (pt)
PT (1)	PT98497B (pt)
SE (1)	SE505734C2 (pt)
TN (1)	TNSN91067A1 (pt)
ZA (1)	ZA915565B (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6090925A (en)	1993-03-09	2000-07-18	Epic Therapeutics, Inc.	Macromolecular microparticles and methods of production and use
US5569467A (en) *	1993-05-15	1996-10-29	Societe De Conseils De Recherches Et D'applications (S.C.R.A.S.)	Process for the preparation of microballs and microballs thus obtained
GB9310030D0 (en) *	1993-05-15	1993-06-30	Scras	Dry processed particles and process for the preparation of the same
ES2188652T3 (es) *	1994-02-28	2003-07-01	Nanopharm Ag	Sistema de direccionado de farmacos, metodos de fabricacion y uso del mismo.
US5980945A (en) *	1996-01-16	1999-11-09	Societe De Conseils De Recherches Et D'applications Scientifique S.A.	Sustained release drug formulations
DE19604744A1 (de)	1996-02-09	1997-08-14	Henkel Kgaa	Technische Di-/Triglyceridgemische
DE19617137C1 (de) *	1996-04-29	1997-02-27	Henkel Kgaa	Verwendung von Copolymerestern für die Herstellung von Mikrosphären
WO1998015263A2 (en) *	1996-10-09	1998-04-16	Takeda Chemical Industries, Ltd.	A method for producing a microparticle
AR012448A1 (es) *	1997-04-18	2000-10-18	Ipsen Pharma Biotech	Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
EP1079967A4 (en)	1998-04-13	2003-07-23	Luminex Corp	LIQUID MARKING USING FLUORESCENT MICROPARTICLES
OA11728A (en) *	1998-12-16	2005-02-01	Aventis Pharma Inc	Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same.
AU5644400A (en) *	1999-09-24	2001-03-29	Rohm And Haas Company	Pellet compositions
US6458387B1 (en) *	1999-10-18	2002-10-01	Epic Therapeutics, Inc.	Sustained release microspheres
ES2326209T3 (es)	2000-10-27	2009-10-05	Baxter Healthcare S.A.	Produccion de microesferas.
US20080026068A1 (en) *	2001-08-16	2008-01-31	Baxter Healthcare S.A.	Pulmonary delivery of spherical insulin microparticles
PT1418890E (pt) *	2001-08-16	2008-06-09	Baxter Int	Formulações de micropartículas à base de propulsor
US20040166077A1 (en) *	2002-12-04	2004-08-26	L'oreal	Process for treating keratin materials with aromatic active principles
FR2848113B1 (fr) *	2002-12-04	2005-02-25	Oreal	Stabilisation de principes actifs aromatiques par des polymeres aromatiques
US20070092452A1 (en) *	2003-07-18	2007-04-26	Julia Rashba-Step	Methods for fabrication, uses, compositions of inhalable spherical particles
AU2004280158B2 (en) *	2003-07-18	2011-02-17	Baxter International, Inc.	Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
US20050142205A1 (en) *	2003-07-18	2005-06-30	Julia Rashba-Step	Methods for encapsulating small spherical particles prepared by controlled phase separation
CA2532874A1 (en) *	2003-07-22	2005-02-03	Baxter International Inc.	Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
US20060135277A1 (en) *	2003-09-10	2006-06-22	Marnocha Bendict F	Golf club and practice arrangement
FR2865938B1 (fr) *	2004-02-05	2006-06-02	Sod Conseils Rech Applic	Formulation retard solide comprenant de l'acetate de triptoreline
US8333995B2 (en) *	2004-05-12	2012-12-18	Baxter International, Inc.	Protein microspheres having injectable properties at high concentrations
JP2007537284A (ja)	2004-05-12	2007-12-20	バクスターインターナショナルインコーポレイテッド	核酸マイクロスフェア、その生成および送達
EP1758558B1 (en) *	2004-05-12	2013-10-16	Baxter International Inc.	Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
US8728525B2 (en) *	2004-05-12	2014-05-20	Baxter International Inc.	Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
EP1773264A1 (en) *	2004-07-13	2007-04-18	Altairnano, Inc	Ceramic structures for controlled release of drugs
CA2573341A1 (en) *	2004-07-13	2006-02-16	Altairnano, Inc.	Ceramic structures for prevention of drug diversion
WO2006050345A1 (en) *	2004-10-29	2006-05-11	Adhesives Research, Inc.	Microscopic tagging system for security identification
WO2006116546A1 (en) *	2005-04-27	2006-11-02	Baxter International Inc.	Surface-modified microparticles and methods of forming and using the same
EP1928814A2 (en) *	2005-08-23	2008-06-11	Altairnano, Inc	HIGHLY PHOTOCATALYTIC PHOSPHORUS-DOPED ANATASE-TiO2 COMPOSITION AND RELATED MANUFACTURING METHODS
US20080038482A1 (en) *	2006-03-02	2008-02-14	Fred Ratel	Method for Low Temperature Production of Nano-Structured Iron Oxide Coatings
WO2007103820A1 (en) *	2006-03-02	2007-09-13	Altairnano, Inc.	Nanostructured indium-doped iron oxide
US20080008843A1 (en) *	2006-03-02	2008-01-10	Fred Ratel	Method for Production of Metal Oxide Coatings
US20070281031A1 (en) *	2006-06-01	2007-12-06	Guohan Yang	Microparticles and methods for production thereof
EP2056883B1 (en)	2006-08-04	2021-09-22	Baxter International Inc.	Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
CA2663589A1 (en) *	2006-10-06	2008-05-22	Baxter International Inc.	Microencapsules containing surface-modified microparticles and methods of forming and using the same
US9017697B2 (en)	2006-10-12	2015-04-28	The University Of Queensland	Compositions and methods for modulating immune responses
US20090169628A1 (en) *	2006-10-17	2009-07-02	Armark Authentication Technologies, Llc	Article and method for focused delivery of therapeutic and/or diagnostic materials
WO2008128000A1 (en) *	2007-04-12	2008-10-23	Altairnano, Inc.	Teflon replacements and related production methods
CN101686939B (zh) *	2007-04-17	2013-03-27	巴克斯特国际公司	用于肺部投送的核酸微粒
US9782300B2 (en)	2008-02-01	2017-10-10	Kci Licensing, Inc.	Fiber-microsphere bioresorbable composite scaffold for wound healing
ES2554168T3 (es)	2008-04-18	2015-12-16	Baxter International Inc.	Composición basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nueva aparición
US8323615B2 (en) *	2008-08-20	2012-12-04	Baxter International Inc.	Methods of processing multi-phasic dispersions
US20100047292A1 (en) *	2008-08-20	2010-02-25	Baxter International Inc.	Methods of processing microparticles and compositions produced thereby
US8367427B2 (en) *	2008-08-20	2013-02-05	Baxter International Inc.	Methods of processing compositions containing microparticles
US8323685B2 (en) *	2008-08-20	2012-12-04	Baxter International Inc.	Methods of processing compositions containing microparticles
US20100078848A1 (en) *	2008-09-29	2010-04-01	Armark Authentication Technologies, Llc	Spinneret and method of spinning fiber
US20100291214A1 (en) *	2008-12-23	2010-11-18	Armark Authentication Technologies, Llc	Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
US20100291384A1 (en) *	2009-05-15	2010-11-18	Armark Authentication Technologies, Llc	Fiber having non-uniform composition and method for making same
CN102481374A (zh) *	2009-05-27	2012-05-30	西莱克塔生物科技公司	具有免疫调节剂的pH敏感释放的靶向合成纳米载体
US20110076771A1 (en) *	2009-09-25	2011-03-31	Armark Authentication Technologies, Llc	Tissue fiber scaffold and method for making
JP6324068B2 (ja)	2010-05-26	2018-05-23	セレクタバイオサイエンシーズインコーポレーテッドＳｅｌｅｃｔａＢｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ．	合成ナノキャリア混合ワクチン
EP2399931A1 (fr) *	2010-06-22	2011-12-28	Ipsen Pharma S.A.S.	Nouveaux composés octapeptidiques et leur utilisation thérapeutique
BR112013010926A2 (pt)	2010-11-01	2016-08-23	Univ Technology Sidney	agentes imunomoduladores e seus usos
CN109172819A (zh)	2011-07-29	2019-01-11	西莱克塔生物科技公司	产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
EP3149049B1 (en)	2014-05-27	2022-10-26	The University Of Queensland	Il-22 for use in treating metabolic disorders
FR3067226B1 (fr) *	2017-06-13	2021-10-08	Rossignol Lange	Element de chaussure de ski

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3567650A (en) *	1969-02-14	1971-03-02	Ncr Co	Method of making microscopic capsules
US4010125A (en) *	1975-06-12	1977-03-01	Schally Andrew Victor	[D-Trp6 ]-LH-RH and intermediates therefor
US4675189A (en) *	1980-11-18	1987-06-23	Syntex (U.S.A.) Inc.	Microencapsulation of water soluble active polypeptides
IE52535B1 (en) *	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
JPS60100516A (ja) *	1983-11-04	1985-06-04	Takeda Chem Ind Ltd	徐放型マイクロカプセルの製造法
IN167096B (pt) *	1985-04-04	1990-09-01	Akzo Nv
US4666705A (en) *	1985-06-03	1987-05-19	E. R. Squibb & Sons, Inc.	Controlled release formulation
GB8628728D0 (en) *	1986-12-02	1987-01-07	Euro Celtique Sa	Spheroids
GB8705083D0 (en) *	1987-03-04	1987-04-08	Euro Celtique Sa	Spheroids
AU4369589A (en) *	1988-10-27	1990-05-03	Abbott Laboratories	Controlled-release delivery device, method for producing device, and method of using device

1990
- 1990-08-01 GB GB909016885A patent/GB9016885D0/en active Pending
1991
- 1991-07-15 IN IN627DE1991 patent/IN178446B/en unknown
- 1991-07-15 IT ITMI911953A patent/IT1251788B/it active IP Right Grant
- 1991-07-16 NZ NZ238981A patent/NZ238981A/en not_active IP Right Cessation
- 1991-07-16 ZA ZA915565A patent/ZA915565B/xx unknown
- 1991-07-19 BE BE9100685A patent/BE1004772A3/fr not_active IP Right Cessation
- 1991-07-22 CH CH2179/91A patent/CH682715A5/fr not_active IP Right Cessation
- 1991-07-22 MY MYPI91001315A patent/MY107500A/en unknown
- 1991-07-23 US US07/734,493 patent/US5213812A/en not_active Expired - Lifetime
- 1991-07-25 LU LU87982A patent/LU87982A1/fr unknown
- 1991-07-26 SE SE9102249A patent/SE505734C2/sv unknown
- 1991-07-30 PT PT98497A patent/PT98497B/pt not_active IP Right Cessation
- 1991-07-30 ES ES09101785A patent/ES2046083B1/es not_active Expired - Fee Related
- 1991-07-30 NL NL9101306A patent/NL194637C/nl not_active IP Right Cessation
- 1991-07-30 TN TNTNSN91067A patent/TNSN91067A1/fr unknown
- 1991-07-30 GR GR910100330A patent/GR1001512B/el not_active IP Right Cessation
- 1991-07-31 FI FI913646A patent/FI104149B/fi active
- 1991-07-31 AU AU81466/91A patent/AU649696B2/en not_active Ceased
- 1991-07-31 IE IE270091A patent/IE65124B1/en not_active IP Right Cessation
- 1991-07-31 KR KR1019910013237A patent/KR920003962A/ko not_active Ceased
- 1991-07-31 AT AT0152591A patent/AT396425B/de not_active IP Right Cessation
- 1991-07-31 NO NO912986A patent/NO300158B1/no not_active IP Right Cessation
- 1991-07-31 DK DK199101418A patent/DK175756B1/da not_active IP Right Cessation
- 1991-08-01 OA OA60055A patent/OA09387A/xx unknown
- 1991-08-01 JP JP3192950A patent/JP2818704B2/ja not_active Expired - Fee Related
- 1991-08-01 DE DE4125542A patent/DE4125542A1/de not_active Withdrawn
- 1991-08-01 FR FR9109773A patent/FR2665360B1/fr not_active Expired - Fee Related
- 1991-08-01 CA CA002048270A patent/CA2048270C/en not_active Expired - Lifetime
- 1991-08-01 MA MA22524A patent/MA22245A1/fr unknown
1994
- 1994-04-11 AU AU59393/94A patent/AU666808B2/en not_active Ceased
- 1994-04-14 HK HK33294A patent/HK33294A/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
US5213812A (en)	1993-05-25
KR920003962A (ko)	1992-03-27
OA09387A (fr)	1992-09-15
AU8146691A (en)	1992-02-06
DK175756B1 (da)	2005-02-14
FR2665360B1 (fr)	1995-02-10
IE65124B1 (en)	1995-10-04
DK141891A (da)	1992-02-02
GR910100330A (en)	1992-08-31
FR2665360A1 (fr)	1992-02-07
FI104149B1 (fi)	1999-11-30
ITMI911953A0 (it)	1991-07-15
FI913646A0 (fi)	1991-07-31
ES2046083A1 (es)	1994-01-16
BE1004772A3 (fr)	1993-01-26
JPH05178740A (ja)	1993-07-20
HK33294A (en)	1994-04-22
ITMI911953A1 (it)	1993-01-15
GR1001512B (el)	1994-02-28
FI104149B (fi)	1999-11-30
AU666808B2 (en)	1996-02-22
SE9102249L (sv)	1992-02-02
JP2818704B2 (ja)	1998-10-30
IE912700A1 (en)	1992-02-12
IN178446B (pt)	1997-05-03
GB9016885D0 (en)	1990-09-12
CH682715A5 (fr)	1993-11-15
CA2048270A1 (en)	1992-02-02
TNSN91067A1 (fr)	1992-10-25
ZA915565B (en)	1992-04-29
MA22245A1 (fr)	1992-04-01
NO912986D0 (no)	1991-07-31
PT98497B (pt)	1997-10-31
NL9101306A (nl)	1992-03-02
DE4125542A1 (de)	1992-02-06
CA2048270C (en)	1997-02-25
IT1251788B (it)	1995-05-26
DK141891D0 (da)	1991-07-31
AT396425B (de)	1993-09-27
ES2046083B1 (es)	1994-08-01
MY107500A (en)	1995-12-30
NO300158B1 (no)	1997-04-21
SE505734C2 (sv)	1997-10-06
SE9102249D0 (sv)	1991-07-26
PT98497A (pt)	1992-06-30
AU649696B2 (en)	1994-06-02
NL194637B (nl)	2002-06-03
NO912986L (no)	1992-02-03
NL194637C (nl)	2002-10-04
ATA152591A (de)	1993-01-15
FI913646L (fi)	1992-02-02
AU5939394A (en)	1994-06-02
NZ238981A (en)	1992-11-25

Publication	Publication Date	Title
BE1004772A3 (fr)	1993-01-26	Procede de preparation de compositions a liberation prolongee et compositions ainsi obtenues.
CA2148823C (en)	1999-03-09	Sustained release microsphere preparation containing antipsychotic drug and production process thereof
US6534081B2 (en)	2003-03-18	Prolonged anesthesia in joints and body spaces
CN1058608C (zh)	2000-11-22	非胃肠道给药药物组合物的制备方法
FR2810885A1 (fr)	2002-01-04	Microparticule a liberation soutenue et procede de fabrication
JPH1179975A (ja)	1999-03-23	マイクロカプセルの調製法
HK188095A (en)	1995-12-22	Prolonged release microcapsules
GB2246514A (en)	1992-02-05	Sustained release particles preparation
EP1450766A1 (fr)	2004-09-01	Microspheres biodegradables a liberation prolongee et leur procede de preparation
US5569467A (en)	1996-10-29	Process for the preparation of microballs and microballs thus obtained
EP0256726B1 (en)	1992-10-07	Encapsulation of trh or its analog
WO1997041836A1 (fr)	1997-11-13	Compositions pharmaceutiques pour la liberation prolongee de principes actifs insolubles
IE940392A1 (en)	1994-11-16	Process for the preparation of microballs and microballs¹thus obtained
JPH04124127A (ja)	1992-04-24	マイクロカプセル型徐放性製剤及びその製造法
JP2003171264A (ja)	2003-06-17	マイクロカプセル及びその製造方法
FR2868704A1 (fr)	2005-10-14	Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires
JPS6341416A (ja)	1988-02-22	鎮痛性ペプチド含有マイクロカプセルの製造法
AU775685B2 (en)	2004-08-12	Prolonged anesthesia in joints and body spaces
WO2003043605A1 (fr)	2003-05-30	Procede de preparation de microparticules sans solvant toxique, microparticules obtenues selon ce procede, utilisations et compositions pharmaceutiques